Procter & Gamble Health Ltd (PGHL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 346859,
    "name": "P & G Health Ltd",
    "stock_name": "P & G Health Ltd",
    "full_name": "Procter & Gamble Health Ltd",
    "name_url": "stocks-analysis/p-g-health",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "5,736.35",
    "chg": -110.05,
    "chgp": "-1.88%",
    "dir": -1,
    "prev_price": "5,846.40",
    "mcapval": "9,521.99 Cr",
    "mcap": "Small Cap",
    "scripcode": 500126,
    "symbol": "PGHL",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE199A01012",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "5.14 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/p-g-health-346859-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P & G Health Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/p-g-health-downgraded-to-hold-by-marketsmojo-amid-valuation-concerns-3733197",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PGHealth_mojoScore_3733197.png",
        "date": "2025-11-27 10:05:56",
        "description": "P & G Health Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, providing investors with a clearer understanding of its current standing."
      },
      {
        "title": "Why is P & G Health Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-p-g-health-ltd-fallingrising-3680801",
        "imagepath": "",
        "date": "2025-11-07 22:17:09",
        "description": "As of 07-Nov, Procter & Gamble Health Ltd's stock price is currently at 5,840.00, reflecting a decline of 148.8 points or 2.48%. The stock has been underperforming, having lost 5.52% over the last five days and is currently lower than its 5-day, 20-day, 50-day, and 100-day moving averages, although it remains above the 200-day moving average. The stock's performance today has also been noted as underperforming its sector by 2.14%. Despite these declines, the company boasts a high management efficiency with a return on equity (ROE) of 27.23%, a low debt-to-equity ratio, and significant institutional holdings at 21.15%, which may provide some stability and confidence among investors.\n\nIn the broader market context, the stock's short-term return of -5.42% over the past week contrasts sharply with the Sensex, which has only declined by 0.86%. While the stock has shown positive year-to-date returns of 11.66%, it..."
      },
      {
        "title": "How has been the historical performance of P & G Health Ltd?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-p-g-health-ltd-3677044",
        "imagepath": "",
        "date": "2025-11-06 22:48:04",
        "description": "Answer:\nThe historical performance of P & G Health Ltd shows a fluctuating trend in net sales and profitability over the years. \n\nBreakdown:\nIn June 2024, P & G Health Ltd reported net sales of 1,151.26 Cr, a decrease from 1,229.62 Cr in June 2023, but an increase from 1,114.41 Cr in June 2022. The total operating income for June 2024 was 1,151.26 Cr, reflecting a similar trend. The company experienced a total expenditure of 845.26 Cr in June 2024, down from 904.94 Cr in June 2023, leading to an operating profit (PBDIT) of 321.63 Cr, which was lower than the 343.07 Cr reported in the previous year. Profit before tax also decreased to 273.32 Cr in June 2024 from 314.20 Cr in June 2023, resulting in a profit after tax of 200.98 Cr, down from 229.47 Cr. The earnings per share (EPS) for June 2024 was 121.07, a decline from 138.23 in June 2023. The company's total assets as of June 2024 were 760.67 Cr, down from..."
      },
      {
        "title": "Are P & G Health Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-p-g-health-ltd-latest-results-good-or-bad-3676417",
        "imagepath": "",
        "date": "2025-11-06 19:16:56",
        "description": "Procter & Gamble Health Ltd's latest financial results for Q2 FY26 present a mixed operational narrative. The company reported a net profit of ₹88.54 crores, reflecting a year-on-year growth of 7.54% compared to ₹82.33 crores in the same quarter last year. However, this growth is less robust than the previous year's 25.56% increase, indicating a potential slowdown in profitability momentum.\n\nIn terms of revenue, net sales stood at ₹324.92 crores, which represents a sequential decline of 4.08% from the previous quarter, although it shows a year-on-year increase of 3.67%. This sequential decline raises questions about demand sustainability and may suggest competitive pressures or seasonality effects impacting sales in key therapeutic segments.\n\nThe operating margin for the quarter improved significantly to 37.02%, marking a substantial expansion of 1,035 basis points quarter-on-quarter, driven by effective co..."
      },
      {
        "title": "Procter & Gamble Health Faces Mixed Financial Trends Amid Profit Growth and Liquidity Strength",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/procter-gamble-health-ltds-financial-trend-declines-from-flat-to-negative-amid-performance-metrics-shift-3675615",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProcterGambleHe_fintrenddot_3675615.png",
        "date": "2025-11-06 11:00:18",
        "description": "Procter & Gamble Health Ltd has shown a flat financial performance for the quarter ending September 2025, despite a notable 35.78% increase in profit after tax to Rs 154.72 crore. The company maintains a strong cash position but faces challenges with a low debtors turnover ratio, impacting operational efficiency."
      },
      {
        "title": "Procter & Gamble Health Q2 FY26: Margin Expansion Drives Strong Profit Growth Despite Revenue Dip",
        "link": "https://www.marketsmojo.com/news/result-analysis/procter-gamble-health-q2-fy26-margin-expansion-drives-strong-profit-growth-despite-revenue-dip-3675375",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProcterGambleHe_quaterlyResult_3675375.png",
        "date": "2025-11-06 09:48:11",
        "description": "Procter & Gamble Health Ltd. reported a robust 33.75% quarter-on-quarter surge in net profit to ₹88.54 crores for Q2 FY26, despite a marginal 4.08% decline in net sales to ₹324.92 crores. The pharmaceutical company, with a market capitalisation of ₹10,060 crores, demonstrated exceptional operational efficiency with operating margins expanding to 37.02% from 26.67% in the previous quarter. Year-on-year, net profit rose 7.54% whilst revenue grew a modest 3.67%, signalling a strategic focus on profitability over top-line expansion."
      },
      {
        "title": "Procter & Gamble Health Adjusts Evaluation Amid Strong Financial Performance and Market Sentiment Shift",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/procter-gamble-health-stock-downgraded-to-hold-amid-technical-grade-shift-3598089",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ProcterGambleHe_mojoScore_3598089.png",
        "date": "2025-10-07 08:25:04",
        "description": "Procter & Gamble Health has experienced a recent evaluation adjustment, indicating a shift in its technical outlook. The company showcases strong management efficiency with a notable return on equity and low debt-to-equity ratio. Despite positive quarterly results, long-term growth appears subdued, with net sales growing at a modest annual rate."
      },
      {
        "title": "Is P & G Health Ltd technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-p-g-health-ltd-technically-bullish-or-bearish-3597281",
        "imagepath": "",
        "date": "2025-10-07 08:11:25",
        "description": "As of 6 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a similar trend on both weekly and monthly time frames. However, the weekly MACD and KST are mildly bearish, which tempers the overall bullish sentiment. The Dow Theory also reflects a mildly bearish stance on the weekly chart, while remaining bullish on the monthly. Overall, the mixed signals suggest a cautious bullish outlook...."
      },
      {
        "title": "Procter & Gamble Health Shows Mixed Technical Trends Amid Strong Long-Term Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/procter-gamble-healths-technical-trend-changes-from-bullish-to-mildly-bullish-amid-stock-price-decline-3597545",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ProcterGambleHe_technicaldot_3597545.png",
        "date": "2025-10-07 08:03:22",
        "description": "Procter & Gamble Health, a small-cap in the Pharmaceuticals & Biotechnology sector, has recently revised its evaluation amid current market conditions. The company has achieved a 16.26% return over the past year, significantly outperforming the Sensex. Its long-term performance shows a remarkable 684.92% return over the last decade."
      }
    ],
    "total": 125,
    "sid": "346859",
    "stock_news_url": "https://www.marketsmojo.com/news/procter-gamble-health-346859"
  },
  "announcements": [
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot",
      "datetime": "18-Nov-2025",
      "details": "Dear Sir Please find attached revised outcome of the postal ballot results declared on November 17 2025 as advised by the exchange.",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot",
      "datetime": "17-Nov-2025",
      "details": "Approval of shareholders for appointment of Mr. Shashank Srowthy as an Executive Director of the Company via postal ballot.",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "17-Nov-2025",
      "details": "Voting results along with report of the scrutinizer for the postal ballot completed on November 16 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Procter & Gamble Health Ltd has declared <strong>450%</strong> dividend, ex-date: 22 Aug 25",
          "dt": "2025-08-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P & G Health Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-11-27 10:05:56

P & G Health Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, providing investors with a clearer understanding of its current standing.

Why is P & G Health Ltd falling/rising?

2025-11-07 22:17:09

As of 07-Nov, Procter & Gamble Health Ltd's stock price is currently at 5,840.00, reflecting a decline of 148.8 points or 2.48%. The stock has been underperforming, having lost 5.52% over the last five days and is currently lower than its 5-day, 20-day, 50-day, and 100-day moving averages, although it remains above the 200-day moving average. The stock's performance today has also been noted as underperforming its sector by 2.14%. Despite these declines, the company boasts a high management efficiency with a return on equity (ROE) of 27.23%, a low debt-to-equity ratio, and significant institutional holdings at 21.15%, which may provide some stability and confidence among investors. In the broader market context, the stock's short-term return of -5.42% over the past week contrasts sharply with the Sensex, which has only declined by 0.86%. While the stock has shown positive year-to-date returns of 11.66%, it...

How has been the historical performance of P & G Health Ltd?

2025-11-06 22:48:04

Answer: The historical performance of P & G Health Ltd shows a fluctuating trend in net sales and profitability over the years. Breakdown: In June 2024, P & G Health Ltd reported net sales of 1,151.26 Cr, a decrease from 1,229.62 Cr in June 2023, but an increase from 1,114.41 Cr in June 2022. The total operating income for June 2024 was 1,151.26 Cr, reflecting a similar trend. The company experienced a total expenditure of 845.26 Cr in June 2024, down from 904.94 Cr in June 2023, leading to an operating profit (PBDIT) of 321.63 Cr, which was lower than the 343.07 Cr reported in the previous year. Profit before tax also decreased to 273.32 Cr in June 2024 from 314.20 Cr in June 2023, resulting in a profit after tax of 200.98 Cr, down from 229.47 Cr. The earnings per share (EPS) for June 2024 was 121.07, a decline from 138.23 in June 2023. The company's total assets as of June 2024 were 760.67 Cr, down from...

Are P & G Health Ltd latest results good or bad?

2025-11-06 19:16:56

Procter & Gamble Health Ltd's latest financial results for Q2 FY26 present a mixed operational narrative. The company reported a net profit of ₹88.54 crores, reflecting a year-on-year growth of 7.54% compared to ₹82.33 crores in the same quarter last year. However, this growth is less robust than the previous year's 25.56% increase, indicating a potential slowdown in profitability momentum. In terms of revenue, net sales stood at ₹324.92 crores, which represents a sequential decline of 4.08% from the previous quarter, although it shows a year-on-year increase of 3.67%. This sequential decline raises questions about demand sustainability and may suggest competitive pressures or seasonality effects impacting sales in key therapeutic segments. The operating margin for the quarter improved significantly to 37.02%, marking a substantial expansion of 1,035 basis points quarter-on-quarter, driven by effective co...

Procter & Gamble Health Faces Mixed Financial Trends Amid Profit Growth and Liquidity Strength

2025-11-06 11:00:18

Procter & Gamble Health Ltd has shown a flat financial performance for the quarter ending September 2025, despite a notable 35.78% increase in profit after tax to Rs 154.72 crore. The company maintains a strong cash position but faces challenges with a low debtors turnover ratio, impacting operational efficiency.

Procter & Gamble Health Q2 FY26: Margin Expansion Drives Strong Profit Growth Despite Revenue Dip

2025-11-06 09:48:11

Procter & Gamble Health Ltd. reported a robust 33.75% quarter-on-quarter surge in net profit to ₹88.54 crores for Q2 FY26, despite a marginal 4.08% decline in net sales to ₹324.92 crores. The pharmaceutical company, with a market capitalisation of ₹10,060 crores, demonstrated exceptional operational efficiency with operating margins expanding to 37.02% from 26.67% in the previous quarter. Year-on-year, net profit rose 7.54% whilst revenue grew a modest 3.67%, signalling a strategic focus on profitability over top-line expansion.

Procter & Gamble Health Adjusts Evaluation Amid Strong Financial Performance and Market Sentiment Shift

2025-10-07 08:25:04

Procter & Gamble Health has experienced a recent evaluation adjustment, indicating a shift in its technical outlook. The company showcases strong management efficiency with a notable return on equity and low debt-to-equity ratio. Despite positive quarterly results, long-term growth appears subdued, with net sales growing at a modest annual rate.

Is P & G Health Ltd technically bullish or bearish?

2025-10-07 08:11:25

As of 6 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a similar trend on both weekly and monthly time frames. However, the weekly MACD and KST are mildly bearish, which tempers the overall bullish sentiment. The Dow Theory also reflects a mildly bearish stance on the weekly chart, while remaining bullish on the monthly. Overall, the mixed signals suggest a cautious bullish outlook....

Procter & Gamble Health Shows Mixed Technical Trends Amid Strong Long-Term Performance

2025-10-07 08:03:22

Procter & Gamble Health, a small-cap in the Pharmaceuticals & Biotechnology sector, has recently revised its evaluation amid current market conditions. The company has achieved a 16.26% return over the past year, significantly outperforming the Sensex. Its long-term performance shows a remarkable 684.92% return over the last decade.

View All News